Amylyx Pharmaceuticals vs Assembly Biosciences
AMLX and ASMB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMLX and ASMB compare
Amylyx Pharmaceuticals is the larger company, worth 7.8 times as much as Assembly Biosciences ($3.4B against $430M).
Assembly Biosciences scores higher on the StockData Score (12 against 7 for Amylyx Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMLX | ASMB |
|---|---|---|
| Size and price | ||
| Market cap | $3.4B | $430M |
| Share price | $30.29 | $21.12 |
| Change, 1 year | 146% | −41.1% |
| Change, 5 years | 182% | −23.5% |
| Beta (5Y) | 1.15 | 1.17 |
| Employees | 136 | 73 |
| StockData Score | ||
| Total score | 7 | 12 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 6.4× |
| P/B | 4.5× | 1.4× (better) |
| FCF yield | – | −9.5% |
| Fair value | – | $22.88 |
| Margin of safety | – | 7.7% |
| Growth | ||
| Revenue growth (TTM) | – | 80.2% |
| Revenue growth, 5Y average | – | −1.8% |
| Profitability | ||
| Operating margin | – | −31.8% |
| Net margin | – | −16.6% |
| FCF margin | – | −60.7% |
| Return on equity | −30.1% | −4.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 26.81 (better) | 12.89 |
| Altman Z-score | 60.09 (better) | 7.10 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 104% | 92.1% |
| Held by insiders | 7.8% | 29.3% |
| Insider net buying, 12 months | −$17.2M | −$252K (better) |
| Short interest, % of float | 12.5% | 21.1% |
Go deeper
- AMLX stock overview
- AMLX income statement
- AMLX valuation and score
- ASMB stock overview
- ASMB income statement
- ASMB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.